Response begins trading on NASDAQ:
This article was originally published in Clinica
Pharmacogenomic cancer diagnostics specialist Response Genetics commenced trading on the NASDAQ capital market last week (June 5) after issuing an initial public offering of 3 million shares of common stock priced at $7 per share. The Los Angeles, California-based firm intends to use the proceeds for research and development, business expansion and general corporate purposes. On first day of trading, its share price reached a high of $7.49 but closed at $7, the original opening price. The company is registered under the symbol "RGDX".
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.